
Cytokines, a broad class of proteins, have a role in fighting infection and in mounting an immune response; in mediating cell differentiation and embryogenesis; in promoting cell growth; and in inhibiting growth or causing cell death. Recent advances in cell culture, monoclonal antibodies and recombinant DNA technology have made it possible to isolate these proteins and to obtain sufficient quantities to conduct clinical studies as well as laboratory experiments. Thus, the foundations have been laid for a new form of cancer therapy and for understanding how abnormalities in the cytokine network could contribute to the process of malignancy. Up-to-date and comprehensive, this book brings together current research and discusses it in the context of its present and potential clinical application. The book is intended for cancer researchers, clinical oncologists, and those involved in the pharmaceutical and biological product industries.
This text investigates the clinical potential and biological mechanisms of cytokines as therapeutic agents in the treatment of malignancy. Author Frances R. Balkwill synthesizes advancements in recombinant DNA technology and monoclonal antibodies to evaluate how cytokine networks influence tumor growth and immune response. The book provides a framework for transitioning laboratory findings into clinical oncology applications, focusing on the dual role of cytokines in both promoting and inhibiting cell proliferation. It serves as a bridge between molecular biology research and practical pharmaceutical development.
What You Will Find
Scope Limits
Experts recognize this work as a foundational reference for understanding the early integration of cytokine research into clinical oncology. Readers frequently note the technical density of the prose, which is tailored specifically for researchers and professionals within the pharmaceutical industry.
Page Count:
320
Publication Date:
1989-08-24
Publisher:
Oxford University Press
ISBN-10:
0192617974
ISBN-13:
9780192617972
No comments yet. Be the first to share your thoughts!